0 0 0
Dieser Online-Shop verwendet Cookies für ein optimales Einkaufserlebnis. Dabei werden beispielsweise die Session-Informationen oder die Spracheinstellung auf Ihrem Rechner gespeichert. Ohne Cookies ist der Funktionsumfang des Online-Shops eingeschränkt. Sind Sie damit nicht einverstanden, klicken Sie bitte hier.

Oya Renal Cell Carcinoma

Molecular Features and Treatment Updates

ISBN: 978-4-431-55530-8

Erscheinungsdatum: Februar 2017

Einband: Hardcover

Seitenzahl: 260 p.

Illustrationen: 56 ill.

Verlag: Springer

Lieferzeit: 2 - 9 Tage

Beschreibung

  • Provides a comprehensive review of diagnosis and treatments of renal cell carcinoma
  • Presents the most recent advances in molecular bases and targeted therapy for renal cell carcinoma
  • Contains important information about pharmacokinetics and pharmacodynamics in molecular- targeted agents of renal cell carcinoma

Renal Cell Carcinoma: Molecular Features and Treatment Updates provide a comprehensive review of diagnosis and treatments of renal cell carcinoma (RCC) for practitioners and researchers with an interest in this disease. A major aim of the book is to present the most important and most recent advances in molecular bases and targeted therapy for this neoplasm. The remarkable resistance to chemotherapy and radiotherapy and the minimum contribution of cancer genes that commonly mutate in other adult epithelial cancers have made RCC highly distinct from other types of solid neoplasms. In the past decade, however, treatment options for RCC have been expanding and moving quickly toward laboratory-based and molecular-targeted therapies. The United States Food and Drug Administration has approved four tyrosine-kinase inhibitors (TKIs), including sorafenib, sunitinib, pazopanib and axitinib and two mTOR inhibitors, including everolimus and temsirolimus. Advances in RCC therapy also have brought novel treatment options to other types of cancer, such as a TKI for hepatocellular carcinoma and gastrointestinal tumors, as well as mTOR inhibitors to progressive neuroendocrine tumors of pancreatic origin and breast cancer, suggesting that RCC is no longer an "orphan disease" in the field of molecular oncology. Additional topics covered in the book include pharmacokinetics and pharmacodynamics in molecular-targeted agents and the putative mechanism of resistance to anti-angiogenic agents, such as intratumoral heterogeneity or cancer stem cell population. This volume provides the latest and most useful information for all readers who are eagerly devoted to curing renal cell carcinoma.